A study published in Nature Immunology demonstrates that durable asthma remission can be achieved with engineered and long-lived chimeric antigen receptor (CAR) T-cell treatment in mice. The study showed that these cells, specifically 5TIF 4 cells, were effective in suppressing inflammation and reducing eosinophils in mouse models of acute and chronic asthma. The engineered T-cells persisted for at least one year and provided long-term effects against asthma-related cytokines. This research highlights the potential of using engineered T-cells for the long-term treatment of non-cancerous diseases like asthma, offering a promising alternative to current treatments that require lifelong administration.
Source link
Single infusion of engineered T-cells achieves lasting asthma remission in mice
